News
CERT
10.71
+1.52%
0.16
Weekly Report: what happened at CERT last week (1216-1220)?
Weekly Report · 9h ago
Is Certara, Inc. (NASDAQ:CERT) Worth US$10.9 Based On Its Intrinsic Value?
Simply Wall St · 3d ago
Certara participates in a conference call with Jefferies
TipRanks · 5d ago
Weekly Report: what happened at CERT last week (1209-1213)?
Weekly Report · 12/16 09:22
Weekly Report: what happened at CERT last week (1202-1206)?
Weekly Report · 12/09 09:21
Certara, Inc. Celebrates Over 100 Publications and Inclusion of 12 Scientists in Stanford/Elsevier's Top 2% of Cited Researchers in 2024
Barchart · 12/03 01:36
Certara Showcases 2024 Research Wins With Over 100 Papers Published
Barchart · 12/02 15:15
Weekly Report: what happened at CERT last week (1125-1129)?
Weekly Report · 12/02 09:21
TimesSquare U.S. Small Cap Growth Q3 2024 Commentary
Seeking Alpha · 11/30 07:30
Weekly Report: what happened at CERT last week (1118-1122)?
Weekly Report · 11/25 09:20
Weekly Report: what happened at CERT last week (1111-1115)?
Weekly Report · 11/18 09:20
Certara (NASDAQ:CERT) Is Reinvesting At Lower Rates Of Return
Simply Wall St · 11/15 10:38
Analysts Forecast 16% Gains Ahead For IYH
NASDAQ · 11/13 12:02
Weekly Report: what happened at CERT last week (1104-1108)?
Weekly Report · 11/11 09:22
CERTARA INC <CERT.O>: JEFFERIES CUTS TARGET PRICE TO $12.50 FROM $15.50
Reuters · 11/11 05:37
Certara’s Balanced Outlook: Hold Rating Amid Strategic Review and Biosimulation Growth
TipRanks · 11/08 07:35
Certara Hold Rating Maintained Amid Mixed Performance and Regulatory Concerns
TipRanks · 11/08 07:29
Forecasting The Future: 4 Analyst Projections For Certara
Benzinga · 11/07 17:00
Certara Is Maintained at Equal-Weight by Barclays
Dow Jones · 11/07 14:59
Certara Price Target Cut to $12.00/Share From $14.00 by Barclays
Dow Jones · 11/07 14:59
More
Webull provides a variety of real-time CERT stock news. You can receive the latest news about Certara, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About CERT
Certara, Inc. is engaged in model-informed drug development. The Company accelerates medicine using biosimulation software, technology and services to transform traditional drug discovery and development. It delivers software products and technology-driven services to customers to efficiently carry out and realize the full benefits of biosimulation in drug discovery, preclinical and clinical research, regulatory submissions and market access. Its regulatory science and market access software and services are underpinned by technologies such as regulatory submissions software, natural language processing and Bayesian analytics. It also develops scientific informatics software products used by the life sciences industry for in-silico research. It develops advanced modeling and biosimulation solutions used to predict the pharmacokinetic and pharmacodynamic properties. Its clients include 2,400 biopharmaceutical companies, academic institutions and regulatory agencies across 66 countries.